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INTRODUCTION
A group of stakeholders met, under
the aegis of the British Society of
Gastroenterology, to discuss the current
landscape of faecal microbiota transplant-
ation (FMT) within the UK and beyond.
The meeting covered a wide range of
topics, ranging from the practical aspects
of establishing an FMT service and regu-
latory issues relating to its delivery, to
research implications and likely future
directions.
CLINICAL EVIDENCE TO DATE
Case report and case series data supportive
of the efficacy of FMT as treatment for
recurrent/refractory Clostridium difficile
infection (CDI) have slowly accumulated
over many decades, but randomised trial
data supporting its use for this indication
were lacking until as recently as 2013.1
There are now a growing number of rando-
mised studies/trials that have consistently
demonstrated the much greater efficacy of
FMT than that of vancomycin in inducing
remission from recurrent/refractory CDI;
success from a single FMT is quoted at
≥80%, and for two FMTs as ≥90%.1 FMT
appears to be similarly as efficacious for
this indication regardless of whether the
transplant is delivered via the upper gastro-
intestinal (GI)1 or lower GI tract.2 3
Based on this clinical evidence (along
with data supporting the cost effective-
ness of FMT in comparison with other
treatment strategies),4 FMT has now
been accepted as an appropriate treat-
ment option for recurrent/refractory CDI
by the National Institute for Health and
Care Excellence,5 Public Health England6
and European guidelines.7
There is increasing recognition that a
distinctive pattern of alteration of the
structure of the gut microbiota (or ‘dys-
biosis’) appears to characterise a number
of conditions, including inflammatory
bowel disease and metabolic syndrome.
Although it remains largely unclear as to
whether these microbiota changes are a
cause of these conditions, consequence
or incidental, there is much interest as to
whether manipulation of the gut micro-
biota might be a successful novel thera-
peutic strategy; however, clinical studies
in this area are largely lacking at present.8
Two recent randomised controlled trials
of FMT as a potential treatment for
ulcerative colitis9 10 were largely negative,
but included microbiota analysis that sug-
gested that only certain stool donors may
be effective, and that matching between
donor and recipient may be required.
ESTABLISHING A CLINICAL FMT
SERVICE
The first session focused on the practical
aspects of setting up a clinical FMT
service, with Dr Benjamin Mullish
sharing his experience of establishing a
service at Imperial College Healthcare
NHS Trust. Although primarily started to
treat patients with recurrent/refractory
CDI within the Trust itself, the paucity of
similar services within the area means
that it has ended up as the primary centre
for this service within North London.
There are very few exclusion criteria
for recipients of FMTwithin this service;
in particular, it was discussed that the
currently available clinical evidence for
immunosuppressed patients receiving
FMT for recurrent CDI has shown a
comparable efficacy and limited adverse
events.11 Imperial have adopted upper GI
administration of FMT of stool that has
been previously processed and frozen in
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glycerol as cryopreservative, an approach that has
been shown to have similar efficacy to transplant
freshly processed stool.3 12 Stool donors are all volun-
teers, and typically workers within the Trust; a
summary of eligibility criteria for acceptance as a
donor is listed within box 1. The discussion focused
on the potential practical difficulties in running a
service, including establishing and maintaining a
screened donor pool, and the ongoing uncertainty
regarding the regulation and governance of FMT
within the UK. Further discussion included the con-
siderable costs involved in maintaining a service,
making it likely to be unfeasible for all hospitals to
offer FMT; only about 10–15 centres within the UK
appear to offer a formalised FMT service at present.
Longer term, a more pragmatic solution for the UK
might be establishment of ‘FMT networks’, with a
‘hub’ that oversees donor management and transplant
preparation, and that treats patients from a number of
regional ‘spoke’ centres.
UNDERSTANDING THE MECHANISMS OF FMT
The second session was presented by Dr Emma
Allen-Vercoe, a microbial ecologist based at the
University of Guelph, Canada. Dr Allen-Vercoe dis-
cussed that while there has been a recent explosion in
literature exploring the changes in the structure of the
gut microbiota in different conditions, there has to
date been more limited work examining the alteration
in the function of the gut microbiota and the inter-
action between the gut microbiota and the physiology
of the host. Interactions between the gut microbiota
and host immunology and metabolism have started to
help explain the efficacy of FMT for CDI, and may
have wider implications as manipulation of the micro-
biota is explored in a range of conditions. Concepts
such as functional redundancy and disability were also
introduced. ‘Functional redundancy’ refers to the pool
of gut microorganisms which may absorb any poten-
tial insults and be replaced by others with little to no
effect on the host, and with no loss of gut microbiota
function. In contrast, ‘functional disability’ describes a
microbial ecosystem with little ability to cope with
any external insult; in humans, this may have been
derived from multiple aetiologies, such as microbiota
depletion as a result of repeated antibiotic use (the
so-called ‘missing microbiota’ hypothesis).13
ROLE FOR FMT IN NON-GASTROINTESTINAL
DISORDERS
Professor Max Nieuwdorp, an endocrinologist based
at the Academic Medical Centre in Amsterdam—and
coauthor on the key first randomised trial for FMT in
treating CDI—presented his work on the potential role
of the gut microbiota in metabolic syndrome. Work in
rodents and now in humans has suggested that FMT
from lean donors may increase insulin sensitivity in
those with metabolic syndrome, and that the delivery
of butyrate-producing bacteria may be the key mechan-
ism underlying this. Butyrate-producing strains of bac-
teria may exert metabolic benefits via a number of
routes, including enhancement of mitochondrial activ-
ity, suppression of metabolic endotoxaemia and/or acti-
vation of intestinal gluconeogenesis.14
Professor Claudia Mauri (from University College
London) discussed the possible implications of the gut
microbiota to rheumatology. IL-1-receptor antagonist
knockout mice raised in a germ-free (ie, bacteria-free)
environment have no joint disease, but rapidly
develop severe T cell arthritis if raised in conventional
housing, or even after exposure to Lactobacillus
bifidus only.15 Dysbiosis has been described in patients
with rheumatoid arthritis, with Porphyromonas gingi-
valis detected in higher amounts in oral mucosa.15
P. gingivalis may have a key mechanistic role in the
onset of rheumatoid arthritis, as it activates enzymes
which may be responsible for protein citrullination;
30% of those positive for anticitrullinated peptide
antibodies will develop rheumatoid arthritis if found
to be positive on screening.
Professor Paul O’Toole—a microbiologist from
University College Cork—discussed the contribution
of the microbiota to human ageing. His research (the
Eldermet project) has shown very distinctive patterns
of microbiota alteration among elderly people in dif-
ferent environments (for instance, between people in
long-term residential care compared with those living
in the community). However, difficulties exist in
designing and interpreting studies in this area—for
instance, is it the person’s living environment that
explains the structure of their microbiota per se, or is
this just a proxy for their diet, medical comorbidities,
etc?
The next topic of discussion was regarding the
brain–gut microbiota axis, a long-standing interest of
Professor John Cryan and his team at University
College Cork. It is increasingly being recognised that
there may be a link between the gut microbiota and a
range of conditions with a neurological component,
Box 1 Key criteria used to evaluate potential stool
donors to a faecal microbiota transplantation
programme:
▸ <50 years old, BMI <30, non-smokers, no alcohol in
<24 hours, no antibiotic use within 3 months.
▸ Health questionnaires—personal, family and travel
history taken to assess eligibility.
▸ Screening of blood (viral hepatitis, HIV, etc) and stool
for pathogens. Screening programme under ongoing
review to ensure suitability and relevance; for
example, recent introduction of screening for gut col-
onisation of multiresistant organisms, including
Carbapenem-resistant enterobacteriaceae (CRE).
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including hepatic encephalopathy, multiple sclerosis,
affective disorders and even irritable bowel syndrome.
In rodents, administration of oral non-absorbable anti-
biotics or FMT produced consistent changes in behav-
iour and alterations in the expression of brain-derived
neurotropic factor.16 Similar results have started to
emerge for the manipulation of the microbiota in
rodent models of neurological and psychiatric disease.
THE FUTURE OF FMT
Despite the efficacy of FMT for recurrent CDI, it evi-
dently has drawbacks, including its unpalatability, the
invasive means of administration and concerns regard-
ing transmission of infection. While oral, capsulised
FMT has started to emerge,17 this still represents a
considerable pill burden in its current form and
remains an essentially untargeted therapy. Of particu-
lar interest, a group from Canada has recently demon-
strated that a ‘stool substitute’ of 33 pure bacterial
strains of commensals isolated from the stool of a
healthy person may have similar efficacy in treating
CDI as a full FMT.18 As the mechanisms underlying
the efficacy of FMT continue to emerge, future direc-
tions may include yet further refinement, perhaps
even to a scenario where bacterial derived products
(eg, enzymes) or metabolites alone might replace
FMT.
REGULATORY AND GOVERNANCE FRAMEWORK
FOR FMT
FMT providers have voiced concerns regarding
ongoing uncertainties regarding the regulation and
‘quality assurance’ of FMT services in the UK and
beyond. Public interest in FMT is high, and already
there has started to be the emergence of unregulated
private FMT clinics, along with reports of home prep-
aration and administration, with the inherent risks
associated with it. Both the British Society of
Gastroenterology and Healthcare Infection Society
have expressed interest in forming a joint regulatory
committee, but none exists at present. Public Health
England have sought to engage with FMT providers
to define standards of good manufacturing practice/
appropriate governance of an FMT service, although
these have not been formalised at present. With a
move in North America towards FMT increasingly
being provided by commercial ‘stool banks’ (such as
OpenBiome)—and interest from a number of parties
in this developing within the UK—such standards will
be of key benefit.
Regulation of FMT within the UK has been
explored by the Human Tissue Authority (HTA) and
the Medicines and Healthcare products Regulatory
Agency (MHRA). The HTA have sought clarification
from the European Commission about whether FMT
would require regulation under the EU Tissues and
Cells Directives; the conclusion was that it would not,
and that FMT therefore fell outside of the HTA’s
remit. The MHRA are currently having an ongoing
dialogue with FMT providers within the UK about
whether FMT is defined as a ‘medicinal product’ or
not, and whether separate regulation for FMTas treat-
ment for CDI and for use in other conditions/within
clinical trials may be more appropriate.
CONCLUSIONS
The huge success of FMT in treatment for CDI has
provided a launch pad for interest in the role of the
gut microbiota in a range of human diseases, GI and
otherwise. Scientifically, the key immediate challenge
is to better understand the function of the gut micro-
biota, and the interaction between the gut microbiota
and the host’s physiology. Clinically, once discussions
regarding regulation have been resolved, refinement
of FMT to a more targeted therapy will be a critical
next step.
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Clinical experience of setting up a faecal microbiota
transplantation (FMT) service—Benjamin Mullish, Imperial
College London
FMT for GI disease (Clostridium difficile infection and IBD)—
Emma Allen-Vercoe, Univ Guelph, Canada
The potential of FMT for metabolic syndrome—Max
Nieuwdorp, Academic Medical Center, Amsterdam
The potential of FMT for rheumatology—Claudia Mauri,
University College London
Microbiota of the ageing subject—changes, health associations
and modulation prospects—Paul O’Toole, Cork
RePOOPulate: the pros and cons of a synthetic gut microbiota
for FMT—Emma Allen-Vercoe, University of Guelph, Canada
FMTand the gut/brain axis—Siobhain O’Mahony, Cork
FMTand the current UK regulatory framework—Victoria
McCune and Peter Hawkey, Public Health England Birmingham
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